


AD-A120 385

ARIZONA UNIV TUCSON DEPT OF CELLULAR AND DEVELOPMEN--ETC F/G 6/20
PREVENTION AND TREATMENT OF VESICATION AND POISONING CAUSED BY --ETC
FEB 81 H V APOSHIAN DAMD17-80-C-0052

NL

UNCLASSIFIED

OF /
AD 3
120885



END
DATE
FORMED
11-82
DTC

AD A120385

DTIC FILE COPY

(12)

AD _____

Prevention and Treatment of Vesication
and Poisoning Caused by Arsenicals

Annual Summary Report

H. V. Aposhian

February 1981

Supported by
U. S. Army Medical Research and Development Command
Fort Detrick
Frederick, Maryland 21701

Contract No. DAMD17-80-C-0052

University of Arizona
Tucson, Arizona
85721

DOD Distribution Statement
Approved for Public Release
Distribution Unlimited

February 1981

Other requests for this document
must be referred to the
Commander, U. S. Army Medical
Research and Development Command
Attn: SORD-SI
Fort Detrick, Frederick, Maryland 21701

DTIC
ELECTE
OCT 18 1982
A

The findings in this report are not to be construed as an
official Department of the Army position unless so designated
by other authorized documents.

82 10 13 030

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

| REPORT DOCUMENTATION PAGE | | READ INSTRUCTIONS BEFORE COMPLETING FORM |
|---|--|--|
| 1. REPORT NUMBER | 2. GOVT ACCESSION NO. <i>AD-A120385</i> | 3. RECIPIENT'S CATALOG NUMBER |
| 4. TITLE (and Subtitle) PREVENTION AND TREATMENT OF VESICATION AND POISONING CAUSED BY ARSENICALS | | 5. TYPE OF REPORT & PERIOD COVERED Annual Summary Report February 1980-January 1981 |
| 7. AUTHOR(s) H. V. Aposhian, Ph.D. | | 6. PERFORMING ORG. REPORT NUMBER |
| 9. PERFORMING ORGANIZATION NAME AND ADDRESS University of Arizona, Dept. of Cellular and Developmental Biology, Tucson, AZ 85721 | | 8. CONTRACT OR GRANT NUMBER(s) DAMD17-80-C-0052 |
| 11. CONTROLLING OFFICE NAME AND ADDRESS U.S. Army Medical Research and Development Command, Fort Detrick, Frederick, MD 21701 | | 10. PROGRAM ELEMENT, PROJECT, TASK AREA & WORK UNIT NUMBERS 62734A.3M162734A875.AP.369 |
| 14. MONITORING AGENCY NAME & ADDRESS (if different from Controlling Office) | | 12. REPORT DATE February 1981 |
| | | 13. NUMBER OF PAGES 36 |
| | | 15. SECURITY CLASS. (of this report) Unclassified |
| | | 15a. DECLASSIFICATION/DOWNGRADING SCHEDULE |
| 16. DISTRIBUTION STATEMENT (of this Report) Approved for public release; distribution unlimited | | |
| 17. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different from Report) | | |
| 18. SUPPLEMENTARY NOTES | | |
| 19. KEY WORDS (Continue on reverse side if necessary and identify by block number) Dimercaptopropanesulfonic acid Dimercaptosuccinic acid Lewisite Arsenic | | |
| 20. ABSTRACT (Continue on reverse side if necessary and identify by block number) <u>Part I</u> - PROTECTION OF MICE AGAINST THE LETHAL EFFECTS OF SODIUM ARSENITE BY 2,3 DIMERCAPTO-1-PROPANE-SULFONIC ACID AND DIMERCAPTOSUCCINIC ACID (DMSA). 2,3 Dimercapto-1-propane-sulfonic acid (DMPS), used by the Soviets since 1956 and virtually unknown in the United States, is a water soluble analog of British Antilewisite. DMPS and dimercaptosuccinic acid (DMSA) are active orally for the protection of mice against the lethal effects of sodium (con't.) | | |

DD FORM 1 JAN 73 1473 EDITION OF 1 NOV 65 IS OBSOLETE

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)


(No. 20 con't.)

arsenite. They are effective whether given before or after the administration of NaAsO_2 . Although D-penicillamine and N-acetyl-DL-penicillamine are useful in the treatment of poisoning by other heavy metals, they are devoid of any protective action under these conditions.

Part II. - A QUANTITATIVE COMPARISON OF A NUMBER OF CHELATING AGENTS

The LD50 of NaAsO_2 is 0.129 mmol/kg, sc, using white mice. The ip administration of the sodium salt of 2,3 dimercapto-1-propanesulfonic acid (DMPS) or meso-dimercaptosuccinic acid (DMSA) (0.80 mmol/kg) immediately after and 90 min after NaAsO_2 increases the LD50 of NaAsO_2 about 4.2- and 4.4-fold, respectively. Neither D-penicillamine nor N-acetyl-DL-penicillamine affects the LD50 of NaAsO_2 under the same conditions. The LD50 of DMPS and DMSA in mice is 5.22 and 13.58 mmols/kg, ip, respectively. The Effective Dose 50 for treating mice 10 min after receiving an LD100 of NaAsO_2 (0.15 mmol/kg) is 0.066 mmol/kg for DMPS and 0.065 mmol/kg for DMSA. The therapeutic index of DMSA against 0.15 mmol/kg NaAsO_2 is 209. This is 2.6 times greater than that of DMPS. The explanation for this difference is that although DMSA is as effective as DMPS, it is less toxic. The LD50 of NaAsO_2 was not increased by sodium diethyldithiocarbamate, α -mercaptopropionylglycine, DL-N-acetylhomocysteinethiolactone or monomercaptosuccinic acid. A series of polymercapto compounds, some having as many as four mercapto groups per molecule also did not protect against the lethality of NaAsO_2 . There is extensive experimental and clinical information about DMPS and DMSA available in the Soviet and Chinese literature where these agents are known as Unithiol or Unithiol and succimer, respectively. We have had many of these papers translated for the USAMRDC.

CONCLUSION - It would appear that DMPS and DMSA warrant further experimental studies and eventually clinical trials for the treatment of intoxication by arsenic, especially against lewisite gas. These agents have been used in human therapy in the Soviet Union and China. Soviet investigators and West German investigators have recommended that it replace BAL for treatment of heavy metal poisoning.



SUMMARY

Purpose: to find ways to prevent vesication and poisoning caused by arsenicals.

Major method up to this stage: Protection of mice against the lethal effects of sodium arsenite.

Summary of results: Part I - PROTECTION OF MICE AGAINST THE LETHAL EFFECTS OF SODIUM ARSENITE BY 2,3 DIMERCAPTO-1-PROPANE-SULFONIC ACID AND DIMERCAPTOSUCCINIC ACID

2,3 Dimercapto-1-propane-sulfonic acid (DMPS), was used by the Soviets since 1956 and virtually unknown in the United States, is a water soluble analog of British Antilewisite. DMPS and dimercaptosuccinic acid (DMSA) are active orally for the protection of mice against the lethal effects of sodium arsenite. They are effective whether given before or after the administration of NaAsO_2 . Although D-penicillamine and N-acetyl-DL-penicillamine are useful in the treatment of poisoning by other heavy metals, they are devoid of any protective action under these conditions.

Part II - A QUANTITATIVE COMPARISON OF A NUMBER OF CHELATING AGENTS

The LD_{50} of NaAsO_2 is 0.129 mmol/kg, sc, using white mice. The ip administration of the sodium salt of 2,3 dimercapto-1-propanesulfonic acid (DMPS) or meso-dimercaptosuccinic acid (DMSA) (0.80 mmol/kg) immediately after and 90 min after NaAsO_2 increases the LD_{50} of NaAsO_2 about 4.2- and 4.4-fold, respectively. Neither D-penicillamine nor N-acetyl-DL-penicillamine affects the LD_{50} of NaAsO_2 under the same conditions. The LD_{50} of DMPS and DMSA in mice is 5.2 and 13.58 mmols/kg, ip, respectively. The Effective Dose 50 for treating mice 10 min after receiving an LD_{100} of NaAsO_2 (0.15 mmol/kg) is 0.066 mmol/kg for DMPS and 0.065 mmol/kg for DMSA.

The therapeutic index of DMSA against 0.15 mmol/kg NaAsO₂ is 209. This is 2.6 times greater than that of DMPS. The explanation for this difference is that although DMSA is as effective as DMPS, it is less toxic. The LD50 of NaAsO₂ was not increased by sodium diethyldithiocarbamate, α-mercap-topropionylglycine, DL-N- acetylhomocysteinethiolactone or monomercapto-succinic acid. A series of polymercapto compounds, some having as many as four mercapto groups per molecule also did not protect against the lethality of NaAsO₂. There is extensive experimental and clinical information about DMPS and DMSA available in the Soviet and Chinese literature where these agents are known as Unithiol or Unitiol and succimer, respectively. We have had many of these papers translated for the USAMRDC.

CONCLUSION - It would appear that DMPS and DMSA warrant further experimental studies and eventually clinical trials for the treatment of intoxication by arsenic, especially against lewisite gas. These agents have been used in human therapy in the Soviet Union and China. Soviet investigators and West German investigators have recommended that it replace BAL for treatment of heavy metal poisoning.

FOREWORD

In conducting the research described in this report, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council (DHEW Publication No. (NIH) 78-23, Revised 1978).

Citations of commercial organizations and trade names in this report do not constitute an official Department of the Army endorsement or approval of the products or services of these organizations.

TABLE OF CONTENTS

| | |
|-----------------------------------|----|
| Summary | 2 |
| Foreword | 4 |
| Table of Contents | 5 |
| Introduction | 6 |
| Materials and Methods for Part I | 8 |
| Materials and Methods for Part II | 9 |
| Results for Part I | 10 |
| Results for Part II | 11 |
| Discussion | 13 |
| Table 1 | 16 |
| Table 2 | 17 |
| Table 3 | 18 |
| Table 4 | 19 |
| Table 5 | 20 |
| Table 6 | 21 |
| Table 7 | 22 |
| Table 8 | 23 |
| Table 9 | 24 |
| Table 10 | 25 |
| Literature Cited | 26 |
| Glossary | 32 |

INTRODUCTION

A number of metal binding agents have been available in the past for the treatment of heavy metal intoxication. For example, dimercaprol (BAL) (1), polyaminocarboxylic acids (2), D-penicillamine (3), and N-acetyl-DL-penicillamine (4) are used for the treatment of humans intoxicated by arsenic (5), lead (6), copper (3), mercury (7), or other heavy metals. Some of these drugs, however, are far from ideal. Since 1943 in the U.S., BAL has remained the drug of choice for the treatment of arsenic poisoning (5), but it has many disadvantages. It is not effective by mouth; its injection, im, is painful; and toxic reactions to it are not uncommon. In the case of the polyaminocarboxylic acids, most of them are ineffective when given by mouth. D-penicillamine has been life saving in the treatment of the inherited disorder hepatolenticular degeneration (3). After a number of years of clinical use, however, it is now evident that D-penicillamine exhibits serious nephrotoxic signs in some patients (49). Thus, there still remains a need for more specific, less toxic, orally active metal binding agents for use in experimental and clinical situations as well as against arsenic containing chemical warfare agents.

Recently, in Western Europe and the United States, there has been a rediscovery of and an increasing interest in the sodium salt of 2,3 dimercapto-1-propanesulfonic acid (DMPS), a water soluble analog of the lipid soluble BAL. The synthesis and metal binding activity of this compound have been reported by Petrunkin (9) in the Soviet Union. Since then, the activity of DMPS in treating intoxication by a number of different heavy metals has been reported, extensively, in the Soviet, Eastern European, and Chinese literature. It has been shown to be

effective in humans when given either by mouth, injection, or aerosol (10). It has been claimed to be an efficient antidote against mercury (10,11,12), arsenic (13), cobalt (14), organic lead (15), polonium (16), chromium (17), silver (18), and copper (19).

DMPS was unavailable in the West until its recent production by Heyl and Co. Its recent availability has encouraged investigators in West Germany, Norway and the U.S. to study the drug with renewed interest. The studies by Soviet investigators have been confirmed and extended in the case of mercury (20,21,22), arsenic (23), and cadmium (24). A pharmacokinetic study of this dimercapto compound has been reported by Klimova (25) and Gabard (26). The latter paper deals with the absorption and distribution of this water soluble BAL analog. In addition, the extracellular distribution of DMPS is demonstrated.

Another water soluble analog of BAL, meso-dimercaptosuccinic acid (DMSA) was first used in 1954 to increase the uptake of antimony in schistosomiasis therapy (27). The first report of its use to treat occupational intoxication by metals was from Peking and Shanghai in 1965 by Shih-Chun et al. (28). They reported that, in humans, DMSA was as effective as Ca EDTA in the treatment of occupational lead poisoning and as effective as DMPS in the treatment of occupational mercury poisoning, judged by increases in the urinary excretion of the offending metal. Its use in mice for acute and prophylactic treatment of arsenic poisoning was reported from Sverdlovsk by Okonishnikova (29) in 1965. The effectiveness of DMSA for treatment of mercury or lead intoxication has been confirmed and extended by a number of groups (30,31,32) as it has for arsenic (23,33), and for cadmium or zinc (34). Pharmacokinetic studies of ³⁵S-DMSA in the rat have been reported by Okonishnikova and Nirenburg (35) in 1974.

In the present paper, the relative effectiveness of a number of metal binding agents, with particular emphasis on DMPS and DMSA, are evaluated quantitatively by determining their activity in changing the LD50 of NaAsO₂ in mice. The therapeutic index of DMPS and DMSA has been determined. In addition, a number of other mercapto compounds, including a series of polymercapto agents, have been tested for their activity in protecting mice against the lethal effects of NaAsO₂.

MATERIALS AND METHODS FOR PART I

DMPS, DMSA, BAL, and N-acetyl-DL-penicillamine were purchased from Aldrich Chemical Co. DMPS was obtained also from Heyl & Co., West Berlin. D-penicillamine was a gift of Eli Lilly & Co. MC&B Reagent Grade sodium arsenite was used.

Male albino mice of the TEX: (ICR) strain were purchased from the Tineco Breeding Labs, Houston, TX. When used in the experiments, they weighed approximately 25-30 g. Food (Wayne Lab-Blox) and tap water were available ad libitum. However, if the chelating agent was to be given orally, the animals were fasted for the previous 12 hours. The animals were maintained at 22°C with 12 hours of alternating light and dark. The amount of NaAsO₂ injected was equal to the approximate LD₁₀₀. The concentration of the NaAsO₂ solution was such that a 25-g mouse received 0.050 ml. The water soluble thiol compounds were dissolved in 0.9% saline immediately before use and the solutions were adjusted to pH 5.5. BAL was dissolved in corn oil. The concentration of the thiol solutions was such that a 25-g mouse received 0.10 ml by the intraperitoneal or oral route. For oral administration, curved 18 gauge oral feeding needles, purchased

from Popper & Sons, New Hyde Park, N.Y., were used. The experiments were performed on different days, with different batches of animals, to confirm and extend the results of previous experiments.

MATERIALS AND METHODS FOR PART II

Animals. Male mice of the Swiss CDL strain (randombred Albino) were obtained from Charles River Mouse Farms, Inc. At the time they were used in the experiments, they weighed approximately 25-30g. Food (Wayne Lab-Blox) and tap water were available ad libitum. The animals were maintained in an air conditioned facility with 12 hrs of alternating light and dark. They were observed and kept for 14 days after the NaAsO_2 injection.

Chemicals. DMPS in the form of its Na salt was a gift of Heyl and Co., Berlin. Since each molecule of NaDMPS has a molecule of H_2O associated with it, a molecular weight of 223.2 was used in mol calculations. DMSA and N-acetyl-DL-penicillamine were purchased from Aldrich Chemical Co., Milwaukee, WI. D-penicillamine was a gift of Lilly Research Center, Ltd., Windlesham, Surrey. DL-thioctic acid and monomercaptosuccinic acid were purchased from Cal Biochem. The polymercapto compounds listed in Table ¹⁰ ~~A~~ were donated by the Evans Chemstries, W. R. Grace & Co., Darien, CT.

Biological studies. The LD_{50} of NaAsO_2 was determined by injecting, sc, various amounts of NaAsO_2 dissolved in 0.9% saline. The concentrations of the solutions were prepared so that a 25g animal would receive 0.050 ml. To determine the effectiveness of a compound in protecting against the lethal effects of NaAsO_2 , the influence of the administration, ip, of that

compound on the LD50 of NaAsO_2 was determined. Solutions of the mercapto compounds were prepared immediately before use in 0.9% saline, adjusted to pH 5.5 using NaOH and the concentration adjusted so that a 25g mouse would receive 0.10 ml. DL-thiotic acid was dissolved using a 10% excess of a 5%, freshly prepared solution of NaHCO_3 . The solution was then brought to volume with 0.9% saline. Injections were made using a 0.25ml glass syringe with a No. 26 needle of 1/2 inch length.

Statistical analysis. Experimental results were analyzed using quantal response methodology. A logistic regression model was used to fit the experimental data and parameters were estimated using the BMDP program package of Dixon and Brown (35) on a CDC Cyber 175 digital computer. Median effective dose and corresponding 95% confidence intervals were estimated following Finney (37).

RESULTS - PART I

None of the mice injected with NaAsO_2 and saline survived (Table 1). The deaths occurred within 43 hours after arsenic administration. DMPS and DMSA were found to be potent protective agents against the lethal action of sodium arsenite (Table 1) when either agent is given intraperitoneally immediately after NaAsO_2 . However, two other well-known, medically useful chelating agents, D-penicillamine and N-acetyl-DL-penicillamine, do not protect (Table 1) under these conditions. The results with these two sulfhydryl compounds are unexpected since there have been three reports of the usefulness of penicillamine in the therapy of arsenic poisoning of humans (38,39,40). However, the clinical reports were based on symptomatic relief. Objective criteria were lacking. None of the metal binding agents

listed in Table 1 is toxic, individually, at these doses, under the conditions of the present experiments (Table 1).

In addition, we have determined that DMPS or DMSA need not be given immediately after NaAsO_2 . The administration of either one of the compounds can be delayed at least 2 hours and still be effective (Table 2). Of even greater importance for any therapeutic or prophylactic potential is that DMPS or DMSA is effective even when given orally and prior to the administration of the arsenic compound (Table 3). Under the present experimental conditions, they are effective as oral prophylactics against arsenic intoxication.

RESULTS - PART II

DMPS or DMSA increase the LD50 of NaAsO_2 . The LD50 of subcutaneously administered NaAsO_2 was found to be 0.132 and 0.127 mmol/kg in two separate experiments (Table 4). When the data of the two experiments were combined and used to determine the LD50, it was found to be 0.129 mmol/kg. The curve is remarkably steep, having a slope of 40.75, if the proportion survival vs dose model is used. The animals that did not survive usually died within three days after injection. When two ip injections of DMPS (0.30 mmols DMPS/kg/injection) are given, one immediately following and the other 90 min after the NaAsO_2 , the LD50 of NaAsO_2 is increased approximately 4.2-fold to 0.533 mmol/kg (Table 5). Under the same conditions, but using DMSA instead of DMPS, the LD50 of NaAsO_2 is increased about 4.4-fold to 0.573 mmol/kg (Table 5). The increase with DMSA is only about 5% more than when DMPS is given. Since the LD50 of NaAsO_2 plus DMPS falls within the confidence interval of the LD50 of NaAsO_2 plus DMSA, it

appears that the effect of DMPS and DMSA on the LD50 of NaAsO_2 is essentially the same under these experimental conditions.

It was also of interest to determine and compare the therapeutic index of DMPS and DMSA. The therapeutic index under these conditions was determined by dividing the LD50 of the dimercapto compound by its ED50. The latter value is defined as the amount of dimercapto compound (mmol/kg) protecting 50% of the animals against the lethal effects of 0.15 mmol NaAsO_2 /kg. This dose of NaAsO_2 , when given, kills 100% of the animals in this laboratory. The LD50 of DMPS, when given ip, was found to be 5.22 mmols/kg (Table ⁶~~A~~). For DMSA, the LD50 is 13.53 mmols/kg (Table ⁷~~A~~). When mice were given NaAsO_2 (0.15 mmol/kg) 30 and 10 min later were treated, ip, with different amounts of DMPS, the ED50 was found to be 0.065 mmol/kg (Table ⁸~~B~~). The ED50 under these conditions for DMSA was 0.065 mmol/kg. The therapeutic index for DMPS or DMSA under these conditions was 79 and 209, respectively. When the DMPS or DMSA was given 35 min after the NaAsO_2 , the therapeutic index was found to be 35 and 115, respectively.

Other mercapto compounds. Other metal binding agents were also tested for their activity in protecting against the lethal effects of NaAsO_2 . Neither D-pen nor N-Ac-DL-Pen changes the LD50 of NaAsO_2 significantly at the 95% level of significance (Table ⁹~~A~~). Other agents (data not shown) that were also found to be ineffective in this respect are the sodium salt of diethyldithiocarbamate, α -mercaptopropionylglycine, DL-N-acetylhomocysteinethiolactone, and monomercaptosuccinic acid.

In general, it has been accepted that a compound with significant antidotal action for arsenic toxicity should have 2 thiol groups. A series of polymercapto compounds having from 2 to 4 mercapto groups per molecule have been obtained and tested for protecting mice against NaAsO_2 . None of

the 7 polythiol compounds (Table 10) were active in protecting mice against an approximate LD100 of NaAsO_2 .

DISCUSSION

The assay of agents that bind and/or mobilize heavy metals can be based on a number of different measurable responses. The basis of one type of assay is the prevention or reversal of the lethal or toxic effects of the particular heavy metal. A second assay is based on the increased excretion of the metal by the putative metal binding agent. There is, however, increasing evidence that supports still another mechanism. Namely, a metal binding agent sometimes forms an insoluble metabolically-inert complex with the metal. The complex, because of its insolubility, is not excreted from the body. It remains in the cell, metabolically-inert and non-toxic. Therefore, it is possible that some metal binding agent might be life saving without increasing the excretion of the metal. This mechanism has been proposed by Gatsch and Harnuth-Hoene (41) to explain the effectiveness of N-acetyl-DL-penicillamine. For these reasons we chose, as the basis of the assay used in the present work, the prevention of the lethal action of NaAsO_2 . Eventually a quantitative comparison will be made of these agents as to their influence on the excretion of ^{74}As .

The results of the experiments reported in this paper clearly show the beneficial effects of DMPS and DMSA in protecting against the lethal effects of NaAsO_2 . Either compound increases by about fourfold the LD50 of NaAsO_2 (Table 2). The ED50 of the two dimercapto compounds is approximately the same when given 10 min after NaAsO_2 (Table 8). A definite difference exists, however, between the LD50 of 5.22 mmols/kg for DMPS and

13.53mmols/kg for DMSA (Tables 3 and 4). This is the reason that the therapeutic index for DMSA is about 2.6 times greater than that for DMPS under these conditions (Table 5). The therapeutic index of either DMPS or DMSA, 70 and 209, respectively, under these conditions, however, is not small. It is conceivable that the therapeutic index might be even greater if smaller doses were given more frequently. The ED50 of DMPS given 10 min or 35 min after NaAsO₂ are essentially similar to each other as well as being similar to the ED50 of DMSA administered 10 min after NaAsO₂. All of these differed from the ED50 of DMSA given 35 min after NaAsO₂ indicating that the pharmacokinetic properties of DMSA must differ from those of DMPS.

While an excellent extensive toxicological study of DMPS in rats has been reported by Planas-Bonne et al. (42), we are not aware of published work dealing with the toxicology properties of DMSA. Such work would be of further value in comparing the efficiency of these two useful dimercapto compounds.

We have not studied BAL under these same conditions since it is lipid soluble while DMPS and DMSA are water soluble. However, BAL is approximately 7 times more toxic than DMPS and 19 times more toxic than DMSA, based on the BAL LD50 of 0.726 mmol/kg, ip (43) and the data of this paper (Tables 6 and 7). Also, Hauser and Wager (44) have estimated BAL to be about 15 times more toxic than DMPS when each was given im to mice. They have also studied the influence of BAL and DMPS on the treatment of arsenic poisoning in mice.

It is of interest to note that the LD50 of DMPS, ip, in mice, as reported in this paper (Table 6) is 5.22 mmols/kg and is comparable to the value of 5.57 mmols/kg obtained by Kostygov (45) and 5.02 mmols/kg, ip, in rats, as reported recently by Planas-Bonne et al. (42).

The DMSA LD50, ip, in mice was found to be 13.53 mmols/kg (Table ⁷A) and compares favorably with 12.1 mmols/kg, ip, found in mice by Shih-Chun et al. (23) in Shanghai and Peking and 14.0 mmols/kg determined by Matsuda (46) in Japan. An LD50 in excess of 16.5 mmols/kg has been reported by Friedheim and Corvi (47). It is not clear whether this latter higher value is due to a difference in the mouse strains used or is due to a higher purity of DMSA.

It is pertinent to point out that the meso form of DMSA has been used in the present study and in most of the published reports concerning DMSA. There is, however, one exception. DL-DMSA has been reported to be more active than meso-DMSA in causing an increase in the excretion of ^{203}Hg , ^{115}Cd , and ^{65}Zn when given to male rats challenged by these metals (34).

In conclusion, DMSA and DMP3 are very effective agents for protecting mice against the lethal effects of NaAsO_2 . Limited published reports from the Soviet Union and mainland China have dealt with their effectiveness in humans intoxicated by heavy metals. DMSA has recently been shown by western investigators to be effective in treating lead intoxication of humans (43). Further human studies of these two dimercapto compounds is not unreasonable and should be encouraged.

These agents should be tested experimentally as antidiotes for lewisite poisoning which our group is now planning with the Aberdeen BML.

Table 1. Protection by DMPS and other thiols against the lethal effects of sodium arsenite. The NaAsO_2 (0.14 mmoles/kg) was injected subcutaneously in the right rear leg. The chelating agent was administered ip immediately after the NaAsO_2 . The chelating agents at these doses were not toxic, per se, as shown by the following data. When saline instead of NaAsO_2 was given, there was 100% survival of animals receiving the following compounds (mmoles/kg) ip: DMPS (0.80); BAL (0.25); DMSA (0.25); D-Pen (0.80); N-Ac-DL-Pen (0.80). There were at least 12 animals in each group.

| Thiol Compound (mmoles/kg) ip | Cumulative 21-day survival No. surviving/No. started | | | | Survival % |
|--|---|-----------|------------|-----------|---------------|
| | Exp I | Exp II | Exp III | Exp IV | |
| (Saline) | 0/12 | 0/12 | 0/12 | 0/12 | 0 |
| 0.80 DMPS | 12/12 | 8/8 | 12/12 | | 100 |
| 0.40 DMPS | 12/12 | | | | 100 |
| 0.25 DMPS | 12/12 | 12/12 | | | 100 |
| 0.14 DMPS | | 12/12 | 9/12 | | 87.5 |
| 0.07 DMPS | | | 8/12 | 11/12 | 79 |
| 0.25 BAL | 11/12 | | | 11/12 | 92 |
| 0.14 BAL | | 1/12 | 1/12 | | 8 |
| 0.25 DMSA | 12/12 | | | 12/12 | 100 |
| 0.14 DMSA | | 12/12 | 8/12 | | 83 |
| 0.07 DMSA | | | 6/12 | 10/12 | 67 |
| 0.80 D-Pen | | | 0/12 | | 0 |
| 0.25 D-Pen | | 0/12 | | | 0 |
| 0.80 N-Ac-DL-Pen | | | 0/12 | | 0 |
| 0.25 N-Ac-DL-Pen | | 0/12 | | | 0 |

Table 2. Experimental therapy with DMPS or DMSA can be delayed after arsenic poisoning. All animals received NaAsO₂ (0.14 mmoles/kg) subcutaneously in the right rear leg. DMPS and DMSA were given ip. At the start of the experiment, when NaAsO₂ was given, there were 10 animals in each group. However, in three of the experimental groups, one animal died before DMPS or DMSA was administered. Therefore, those groups are listed with 9 instead of 10 started.

| Dithiol and time after NaAsO ₂ it was given | Cumulative 21-day survival <u>No. surviving/No. started</u> | | Survival % |
|--|--|--------|---------------|
| | Exp I | Exp II | |
| (Saline) | 0/10 | 0/10 | 0 |
| 0.25 DMPS | | | |
| at 60 min | 9/10 | 7/9 | 84 |
| at 90 min | 9/10 | 9/9 | 95 |
| at 120 min | 8/10 | 9/10 | 85 |
| 0.25 DMSA | | | |
| at 60 min | 7/9 | 8/10 | 79 |
| at 90 min | 9/10 | 10/10 | 95 |
| at 120 min | 5/10 | 6/10 | 55 |

Table 3. Prophylactic and oral activity of DMPS or DMSA. The NaAsO₂ (0.14 mmoles/kg) was administered subcutaneously in the right rear leg. DMPS or DMSA was given orally fifteen minutes prior to the NaAsO₂. The survival of control animals receiving 1.0 mmoles of DMPS per kg and saline, instead of NaAsO₂, was 100%.

| Thiol Compound (mmoles/kg) oral | Cumulative 21-day survival No. surviving/No. started | | | Survival % |
|--|---|-------|-------|---------------|
| | Exp 1 | Exp 2 | Exp 3 | |
| (saline) | 0/8 | 0/10 | 0/10 | 0 |
| 1.0 DMPS | 8/8 | 8/10 | | 89 |
| 0.75 DMPS | | 8/10 | | 80 |
| 0.50 DMPS | | 6/10 | 10/10 | 80 |
| 0.25 DMPS | | 10/10 | 7/10 | 85 |
| 0.12 DMPS | | 0/10 | | 0 |
| 1.0 DMSA | 8/8 | | | 100 |
| 0.50 DMSA | | | 10/10 | 100 |
| 0.25 DMSA | | | 8/10 | 80 |
| 0.12 DMSA | | | 4/10 | 40 |

TABLE 4

LD50 OF SODIUM ARSENITE IN THE MOUSE

| NaAsO (mmol/kg,sc) | Exp. 1 <u>Dead</u> Started | Exp. 2 <u>Dead</u> Started | Summation <u>Dead</u> Started |
|----------------------------|----------------------------------|----------------------------------|-------------------------------------|
| 0.03 | 0/3 | --- | 0/3 |
| 0.09 | 0/3 | --- | 0/3 |
| 0.10 | 0/3 | 0/12 | 0/20 |
| 0.11 | 0/3 | --- | 0/3 |
| 0.12 | 1/3 | 2/12 | 3/20 |
| 0.13 | 3/3 | 7/12 | 10/20 |
| 0.14 | 7/3 | 12/12 | 19/20 |
| 0.16 | --- | 12/12 | 12/12 |
| LD50 (mmol/kg) | 0.1315 | 0.1274 | 0.1290 |
| 95% Confidence Interval | (0.122,0.260) | (0.030,0.131) | (0.125,0.139) |

2 In subsequent tables of this paper, the data represent the combined results of a number of separate experiments. The combined results were used to calculate the LD50 listed in the tables. This has been done to take advantage of the larger number of animals, resulting from combination of the data, for calculation of median doses and statistical evaluation of data. In addition, it also saved space in this paper. The reason for the number of animals in some groups differing from the number in other groups in the same table is that very often the combined data are the result of from 2-4 separate experiments in which different numbers of animals were used in each experiment. Otherwise, the experiments were performed under identical conditions.

TABLE 5

2,3 DIMERCAPTO-1-PROPANE SULFONATE OR MESO-DIMERCAPTOSUCCINIC
ACID INCREASES THE LD50 OF SODIUM ARSENITE^a

| NaAsO ₂ (mmol/kg, 30) | DMPS | DMSA |
|-------------------------------------|-----------------|-----------------|
| | Dead Started | Dead Started |
| 0.35 | 0/12 | 2/24 |
| 0.40 | 5/24 | 3/24 |
| 0.45 | 0/12 | 3/35 |
| 0.45 | 2/12 | ---- |
| 0.50 | 3/24 | 5/24 |
| 0.55 | 13/24 | 11/35 |
| 0.60 | 13/24 | 15/35 |
| 0.65 | ---- | 10/12 |
| 0.70 | 23/24 | 33/35 |
| 0.75 | ---- | 12/12 |
| LD50 (mmol/kg) | 0.538 | 0.573 |
| 95% Confidence Interval | (0.492, 0.590) | (0.443, 0.703) |

^aDMPS or DMSA, 0.30 mmol/kg, was given, ip, immediately after and 30 mins after NaAsO₂.

TABLE 5

LD50 OF DIMERCAPTOPROPANESULFONATE IN MICE

| DAPS (mmols/kg, ip) | <u>Dead</u> Started |
|----------------------------|------------------------|
| 3.3 | 0/3 |
| 4.0 | 0/3 |
| 5.0 | 7/16 |
| 5.5 | 5/3 |
| 6.0 | 7/3 |
| 6.6 | 15/16 |
| 7.0 | 3/3 |
| 9.9 | 3/3 |
| LD50 (mmols/kg) | 5.22 |
| 95% Confidence Interval | (4.35, 5.51) |

TABLE 7

LD50 OF MESO-DIMERCAPTOSUCCINIC ACID IN MICE

| DMSA (nmols/kg, ip) | <u>Dead</u> Started |
|----------------------------|------------------------|
| 5.0 | 0/32 |
| 12.0 | 3/32 |
| 13.0 | 5/12 |
| 14.0 | 3/12 |
| 15.0 | 13/24 |
| 18.0 | 17/20 |
| 24.0 | 32/32 |
| LD50 (nmols/kg) | 13.58 |
| 95% Confidence Interval | 11.35, 15.22 |

TABLE 8

DETERMINATION OF THE ED50 AND THERAPEUTIC INDEX OF
2,3-DIMERCAPTO-1-PROPANE SULFONIC ACID, NaSALT, AND
MESO-DIMERCAPTOSUCCINIC ACID WHEN GIVEN 10 MINUTES OR
35 MINUTES AFTER 0.15 MMOLS NaAsO₂/KG

| Dimercapto Agent | DMPs +10 min | DISA +10 min | DAPS +35 min | DMSA +35 min |
|------------------------|---------------------------------|-------------------|-------------------|-------------------|
| (mmol/kg, ip) | number surviving/number started | | | |
| 0.010 | --- | 0/24 | --- | 0/12 |
| 0.015 | 0/36 | --- | 3/36 | --- |
| 0.030 | 1/36 | 5/24 | 7/36 | 1/30 |
| 0.040 | --- | 5/24 | --- | --- |
| 0.045 | 5/24 | --- | 3/24 | --- |
| 0.050 | --- | 10/24 | --- | --- |
| 0.060 | 5/24 | 13/24 | 13/24 | 5/38 |
| 0.0675 | 15/24 | --- | --- | --- |
| 0.070 | --- | 9/23 | --- | --- |
| 0.075 | 21/24 | --- | 15/24 | --- |
| 0.090 | --- | 13/24 | --- | 5/12 |
| 0.090 | 20/24 | --- | 15/24 | 3/10 |
| 0.100 | --- | --- | --- | 15/28 |
| 0.105 | 31/36 | --- | 30/36 | --- |
| 0.120 | 35/36 | --- | 34/36 | 3/12 |
| 0.125 | --- | 21/24 | --- | 13/17 |
| 0.150 | --- | --- | --- | 21/30 |
| 0.150 | --- | --- | --- | 5/30 |
| 0.200 | --- | --- | --- | 37/46 |
| 0.300 | --- | --- | --- | 35/39 |
| ED50 (mmol/kg) | 0.066 | 0.065 | 0.061 | 0.113 |
| Confidence Interval | (0.059- 0.072) | (0.040- 0.085) | (0.043- 0.072) | (0.071- 0.154) |
| Therapeutic Index | 73 | 209 | 35 | 115 |

TABLE 9

NEITHER D-PENICILLAMINE NOR N-ACETYL-DL-PENICILLAMINE
INCREASES THE LD50 OF SODIUM ARSENITE¹

| | none | D-Pen | N-Ac-DL-Pen |
|--------------------------------------|------------------------|------------------------|------------------------|
| NaAsO ₂ (mmols/kg, sc) | <u>Dead</u> Started | <u>Dead</u> Started | <u>Dead</u> Started |
| 0.10 | 0/12 | 0/3 | 0/3 |
| 0.12 | 2/12 | 5/3 | 1/3 |
| 0.13 | 7/12 | 7/3 | 5/3 |
| 0.14 | 12/12 | 3/3 | 4/3 |
| 0.15 | 12/12 | 3/3 | 3/3 |
| 0.20 | — | 3/3 | 3/3 |
| LD50 (mmol/kg) | 0.127 | 0.119 | 0.133 |
| 95% Confidence Interval | (0.030, 0.131) | (0.073, 0.191) | (0.054, 0.142) |
| Combined LD50 (mmol/kg) | 0.125 | | |
| 95% Confidence Interval | (0.1171, 0.1313) | | |

¹D-pen or N-Ac-DL-pen (0.30 mmols/kg) was given, ip, immediately following and at 30 min after the metal binding agent.

TABLE 10

POLYTHIOL COMPOUNDS THAT DO NOT PROTECT AGAINST THE LETHAL EFFECTS
OF 0.14 MMOL SODIUM ARSENITE PER KG^a

| Sulphydryl Compound Tested | Chemical Structure | Dose (mmol/kg) |
|--|--|-------------------|
| Pentaerythritol tetraethioglycolate | $C(CH_2OOCCH_2-SH)_4$ | 0.50 |
| Trinethylol propane trithioglycolate | $CH_3CH_2C(CH_2OOCCH_2-SH)_3$ | 0.50 |
| Glycol dimercapto- propionate | $H_2COOCCH_2CH_2-SH$ $H_2COOCCH_2CH_2-SH$ | 0.25 |
| Glycol dimercapto- acetate | $H_2COOCCH_2-SH$ $H_2COOCCH_2-SH$ | 0.50 |
| Trisethylolethane trithioglycolate | $CH_3C(CH_2OOCCH_2-SH)_3$ | 0.50 |
| Pentaerythritol tetra- (3-mercaptopropionate) | $C(CH_2OOCCH_2CH_2-SH)_4$ | 0.50 |
| Trinethylpropane tri- (3-mercaptopropionate) | $CH_3CH_2C(CH_2OOCCH_2CH_2-SH)_3$ | 0.50 |

^aEach polythiol compound was dissolved in peanut oil and administered ip at the dose indicated. $NaAsO_2$ was given sc. The mortality of animals receiving $NaAsO_2$ (0.14 mmol/kg) plus peanut oil or $NaAsO_2$ plus the indicated thiol compound was 100%. There was 0% mortality for animals receiving any one of the sulphydryl compounds at the dose stipulated out in the absence of $NaAsO_2$. There were 3 mice per group.

LITERATURE CITED

1. Peters, R.A. and Stocken, L.A. (1947). Preparation and pharmacological properties of 4-hydroxy-methyl-2-(3'-amino-4'-hydroxyphenyl)-1,3-dithia-2-arsacyclopentane (napharside-BAL compound). Biochem. J. 41, 53-55.
2. Chenoweth, M.D. (1953). Clinical uses of metal-binding drugs. Clin. Pharmac. Ther. 9, 355-337.
3. Walshe, J.M. (1956). Penicillamine, a new oral therapy for Wilson's disease. Am. J. Med. 21, 437-495.
4. Aposhian, H.V. and Aposhian, M.M. (1959). N-acetyl-DL-penicillamine, a new oral protective agent against the lethal effects of mercuric chloride. J. Pharmacol. Exp. Ther. 126, 131-135.
5. Klaassen, C.D. (1930). Heavy metals and heavy-metal antagonists. In The Pharmacological Basis of Therapeutics (A.G. Gilman, L.S. Goodman and A. Gilman, eds.) pp. 1615-1637, Macmillan, New York.
6. Chisholm, J.J., Jr. (1957). Treatment of lead poisoning. Mod. Treat. 4, 710-727.
7. Goldblatt, D., Greenwood, M.R., and Clarkson, T.W. (1971). Chronic metallic mercury poisoning treated with N-acetyl-DL-penicillamine. Neurology. 21, 439.
8. Walshe, J.M. and Cummings, J.N. (1961). Wilson's Disease, some current concepts. Blackwell, Oxford.
9. Petrunkin, V.E. (1956). Synthesis and properties of dimercapto derivatives of alkylsulfonic acids. Ukr. Khim. Zhurn. 22, 603-607.
10. Ashbel, S.I. (1959). Unithiol in prophylaxis and therapy of occupation conditioned poisoning with mercury and its organic compounds. In Tiоловые soyedineniya v meditsine (M.M. Luganskiy, V.E. Petrunkin,

P.V. Rodionov and A.J. Cherkas, eds.) pp. 151-153. Kiev: Gos. Med. Izd. Ukrain, SSR.

12. Belonozhko, J.A. (1953). Therapeutic action of unithiol in poisoning with inorganic mercury compounds. Farmakol. i Toksikol 21, 59-73.
13. Lunganski, M.I. and Loboda, Y.I. (1951). Effect of unithiol and its analogs on SH groups in the blood serum of rabbits in conditions of arsenic poisoning. Ukrain. Biokhim. Zhurn. (Kiev) 33, 315-325.
14. Cherkas, A.I. and Braver-Chernobul'skaya, B.S. (1953). Unithiol--A cobalt antidote. Farmakol. i Toksikol. (Moscow) 21, 59-63.
15. Okonishnikova, I.Y., Rozenberg, E.E., and Rezina, I.A. (1975). The therapeutic-prophylactic effect of succimer in experimental subacute lead acetate poisoning. Gig. Tr. Prof. Zabol 3, 24-28.
16. Zotova, M.G. (1953). Effect of unithiol on the elimination of Pb^{410} , Med. Radiologiya 3, 57-58.
17. Sarkisian, A.A., Epremian, G.A., and Simavorian, P.S. (1971). Biochemical and morphologic changes in kidneys in chromium poisoning and therapeutic effectiveness of unithiol. Zhurnal Eksperimentalnoi i Klinicheskoi Meditsiny. 11, 25-31.
18. Romanov, S.S., (1967). Unithiol as an antidote in pulmonary edema secondary to intravenous injection of silver nitrate. Farmakol. Toksikol. 30, 237-238.
19. Angelova, E. and Stoytchev, T. (1973). Experimental studies on the antidotal and copper-decorporating effects of Unithiol upon acute poisoning with copper sulfate and the influence of acidoses and alkaloses on these effects. Bulgarian Acad. Sciences. 15, 179-186.
20. Gabard, B. (1975). Treatment of methylmercury poisoning in the rat with sodium 2,3-dimercaptopropionate-1-sulfonate: Influence of dose and mode of

- administration. Toxicol. appl. Pharmacol. 33, 415-424.
21. Battistone, G.C., Miller, R.A., and Rubin, M. (1977). The use of 2,3, dimercaptopropane sodium sulfonate (DMPS) in mercury chelation therapy. In Clinical Chemistry and Chemical Toxicology of Metals (S.G. Brown, ed.) pp. 221-224. Elsevier Press.
 22. Jones, M.M., Basinger, M.A., Weaver, A.D., Davis, C.M., and Vaughn, M.K. (1980). Comparison of standard chelating agents for acute mercuric chloride poisoning in mice. Research Commun. Chem. Path. and Pharm. 27, 353-372.
 23. Taillock, C.H. and Aposhian, H.V. (1980). Protection of mice against the lethal effects of sodium arsenite by 2,3 dimercapto-1-propane-sulfonic acid and dimercaptosuccinic acid. Biochem. Biophys. Res. Comm. 94, 501-507.
 24. Jones, M.M., Weaver, A.D., and Weller, W.L. (1973). The relative effectiveness of some chelating agents as antidotes in acute cadmium poisoning. Res. Commun. Chem. Path. and Pharmacol. 22, 531-533.
 25. Klinova, L.K. (1959). Materially k farmakologii unitiola. In: Tiоловые soyedineniya v meditsine. Ed.: M.N. Luganskiy, V.E. Petrunkin, P.V. Rodionov, and A.J. Cherkas. Gos. Med. Izd. Ukrain. SSR, Kiev, pp.135-138.
 26. Gabard, B. (1973). Distribution and excretion of the mercury chelating agent sodium 2,3-dimercaptopropane-1-sulfonate in the rat. Arch. Toxicol. 39, 239-293.
 27. Friedheim, E., DaSilva, J.R., and Martins, A.V. (1954). Treatment of Schistosomiasis Mansoni with antimony-a a-dimercapto-potassium succinate (TNSb). Amer. J. Trop. Med. Hyg. 3, 714-727.

28. Shih-Chun, W., Kuang-Sheng, T., and Chih-Chung, I. (1965). Chelating therapy with NaDIS in occupational lead and mercury intoxication. Chin. Med. J. 34, 437-439.
29. Okonishnikova, I.Y. (1965). Experimental therapy and prophylaxis of acute poisoning with arsenic compounds. Siz. Tr. Prof. Zabol 9, 33-43.
30. Friedheim, E. and Corvi, C. (1975). Meso-dimercaptosuccinic acid, a chelating agent for the treatment of mercury poisoning. J. Pharm. Pharmac. 27, 524-525.
31. Magos, L. (1975). The effects of dimercaptosuccinic acid on the excretion and distribution of mercury in rats and mice treated with mercuric chloride and methyl-mercury chloride. Br. J. Pharmac. 55, 479-484.
32. Aaseth, J. and Friedheim, E.A.H. (1973). Treatment of methyl mercury poisoning in mice with 2,3-dimercaptosuccinic acid and other complexing thiols. Acta Pharmacol. et Toxicol. 42, 248-252.
33. Graziano, J.H., Cuccia, D., and Friedheim, E. (1973). The pharmacology of 2,3-dimercaptosuccinic acid and its potential use in arsenic poisoning. J. Pharmacol. and Expt. Therap. 207, 1051-1055.
34. Egorova, L.G., Okonishnikova, I.E., Nirenburg, V.L., and Postovskii, I.Y. (1972). Complex formation of certain metals with dimercaptosuccinic acid stereoisomers. Khimiko Farmatseviticheskii Zhurnal. 6, 14-16.
35. Okonishnikova, I.Y. and Nirenburg, V.L. (1974). Absorption, distribution, and excretion of S-mesodimercaptosuccinic acid (succimer). In Voprosy Eksp. Klin. Ter. Profil. Prom. Intoksikatsii, (B.T. Velichkovskii, ed.), Sverdlovsk, USSR., pp. 11-14.
36. Dixon, W.I. and Brown, M.B. (1979). Biomed. Comp. Prog. P-Series, Univ. California Press, Los Angeles.

37. Finney, D.J. (1955). Experimental Design and Analysis of Experiments, The University of Chicago Press, Chicago.
38. St. Petery, J., Rennert, O.M., Choi, H., and Wolfson, S. (1970). Clin. Toxicol. 3, 519-526.
39. Kuruvilla, A., Bergeson, P.S., and Done, A.K. (1975). Clin. Toxicol. 3, 533-540.
40. Peterson, R.G. and Rumack, B.H. (1977). J. Pediatr., 91, 661-666.
41. Catsch, A. and Harmuth-Hoene, A.E. (1979). Pharmacology and Therapeutic Applications of Agents Used in Heavy Metal Poisoning in The Chelation of Heavy Metals. (W.G. Levine, ed.) pp. 107-224, Pergamon Press, Oxford.
42. Planas-Johne, F., Gabard, B., and Schaffer, E.H. (1980). Toxicological studies on sodium 2,3-dimercaptopropane-1-sulfonate in the rat. Arzheim.-Forsch.-Drug Res. 30, 1291-1294.
43. Zvirblis, P. and Ellin, R.I. (1976). Acute systemic toxicity of pure dimercaprol and trimercapto propane. Toxicol. Appl. Pharmacol. 36, 397-399.
44. Hauser, W. and Wager, N. (1979). 7th Internatl. Congr. Pharmacol. Paris, Treatment of arsenic poisoning in mice with sodium dimercapto-1-sulfonate.
45. Kostygov, N.M. (1953). The antidotal action of mercaptosuccinic acid and Unithiol against mercury. Farmakol. i Toksikol. 21, 64-69.
46. Matsuda, Y. (1953). Experimental study on sodium dimercaptosuccinic acid. Gifu Daigaku Igakubu Kiyo 1, 859-883.
47. Friedheim, E., Corvi, C., and Wakker, C.H. (1976). Meso-dimercaptosuccinic acid a chelating agent for the treatment of mercury and lead poisoning. J. Pharm. Pharmac. 29, 711-712.
48. Friedheim, E., Graziano, J.H., Popovac, D., Dragovic, D., and Kaul, B.

(1973). Treatment of lead poisoning by 2,3-dimercaptosuccinic acid.

Lancet II, 1234-1235.

49. Elsas, L.J., Hayslett, J.P., Spargo, B.H., Durant, J.L., and Rosenberg, L.E.

(1971). Wilson's disease with reversible renal tubular dysfunction.

Correlation with proximal tubular ultrastructure. Ann. Intern. Med.

75, 427-433.

GLOSSARY

Abbreviations:

| | |
|-------------|---|
| DMPS | 2,3 dimercapto-1-propane-sulfonic acid, Na salt |
| DMSA | dimercaptosuccinic acid |
| BAL | British Antilewisite or 2,3-dimercaptopropanol |
| D-pen | D-penicillamine |
| N-Ac-DL-Pen | N-acetyl-DL-penicillamine |

Distribution List

4 copies: Commander
 US Army Medical Research and Development Command
 ATTN: SGRD-RMS
 Fort Detrick, Frederick, MD 21701

5 copies: Commander
 US Army Medical Research and Development Command
 ATTN: SGRD-PLE
 Fort Detrick, Frederick, MD 21701

12 copies: Administrator
 Defense Technical Information Center
 ATTN: DTIC-DDA
 Cameron Station
 Alexandria, VA 22314

1 copy: Commandant
 Academy of Health Sciences, US Army
 ATTN: AHS-CDM
 Fort Sam Houston, TX 78234

1 copy: Dean, School of Medicine
 Uniformed Services University of the Health Sciences
 4301 Jones Bridge Road
 Bethesda, MD 20014